secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001140361-25-026864
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud

Elevation Oncology completes acquisition by Concentra Biosciences, shares delisted
--------------------------------------------------------------------------------

- Concentra Biosciences acquires Elevation Oncology for $0.36 per share plus contingent value right (CVR).
- 67.09% of shares tendered in the offer, satisfying the Minimum Tender Condition.
- All directors resign at closing; Kevin Tang becomes sole director of the surviving corporation.
- CEO/CFO Tammy Furlong terminated without cause, receives 12 months salary plus $600,000 lump sum.
- Company requests delisting from Nasdaq and deregistration under Exchange Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/ef20052364_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-026864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer